Introduction
============

Colorectal cancer (CRC) is the third most common cause of cancer-related death in the US [@B1]. One out of four patients presenting with conventionally staged node negative disease (AJCC Stage I and II), and over 50% of patients with Stage III disease will develop local recurrence and/ or metastases[@B2],[@B3]. Across all stages, approximately 30% of patients will develop distant metastases[@B2]. Once metastases become clinically evident prognosis is often fatal. Moreover, in spite of the fact that modern systemic therapies for CRC have resulted in improved overall survival (OS), failure rate in the adjuvant setting is 30% for high-risk Stage II and Stage III patients, and overall response rate is only 60% for patients with Stage IV CRC [@B4],[@B5],[@B6]. A significant advance in the care of patients will be realized by biomarkers that can accurately identify patients at-risk for disease recurrence and dissemination, and those that fail to respond to systemic therapy. These patients might benefit from early (preventative) treatment, alternative treatment strategies, and/or frequent surveillance for and early detection of disease recurrence.

Extensive CRC research over the last decade has suggested promising biomarkers[@B7]. Although many biomarkers exist, only a select few have provided prognostic data. This list includes markers such as tumor MSI-H expression (defects in DNA mismatch repair, MSI phenotype), 18q AI expression, p53 expression and KRAS mutation. MSI-H phenotype has been associated with improved clinical outcome (disease-free and overall survival) [@B8],[@B9]. Some published data supports the recommendation not to administer chemotherapy to Stage II patients with a MSI-H primary colon cancer [@B10]. The overall predictive value of MSI-H phenotype is currently being tested in the Eastern Cooperative Oncology Group Trial 5202 (E5202) adjuvant CRC trial [@B7]. This trial is specifically intended to identify patients with AJCC Stage II CRC most likely to respond to adjuvant systemic therapy.

Tumor expression of 18q AI has also been associated with decreased survival and is also being tested in the E5202 trial[@B7]. Furthermore, p53 mutation or overexpression has been associated with poor prognosis, including decreased disease free survival (DFS), recurrence free survival (RFS) and overall survival (OS)[@B7]. Although KRAS itself is not a prognostic factor in CRC, patients with wild-type KRAS tumors have been found to respond to and benefit from certain targeted adjuvant systemic therapies[@B7],[@B11],[@B12]. That being said, the overall poor survival of advanced CRC patients establishes the need for improved prognostic and predictive biomarkers.

The precise cell of origin of CRC remains unknown. Recently, compelling evidence has emerged in support of the cancer stem cell (CSC) hypothesis in several solid organ epithelial malignancies including CRC[@B13],[@B14],[@B15]-[@B18]. The CSC hypothesis posits that CSCs are responsible for tumor initiation, metastases and resistance to treatment leading to disease relapse following surgery and/or chemoradiotherapy[@B19]. The traditional, stochastic model of tumorigenesis suggests that all cells within a tumor are capable of tumor initiation and propagation[@B20]. The CSC hypothesis proposes a hierarchical model, in which only a small fraction of cells (CSC) are capable of tumor propagation[@B20]. The CSC hypothesis therefore raises questions regarding current diagnostic and therapeutic modalities, suggesting that the CSC is a rational target for the development of more efficacious screening, early detection, prevention, treatment and surveillance modalities and interventions[@B20],[@B21]. Based on the tenets of the CSC hypothesis, identification, proper selection, characterization, testing, biological implications and validation of CRC derived CSC (CRCSC) are imperative for improving early detection, screening, risk stratification prognostication and individualized prediction of treatment response.

Properties that define potential CSCs are: \[1\] self-renewal; \[2\] the capacity for differentiation (allowing for recapitulation of all cell types of the original tumor); \[3\] tumor initiating capacity; and, \[4\] asymmetric cell division via non-random chromosomal co-segregation[@B16],[@B22]. Investigators have used these properties and various membrane and cytoplasmic markers to isolate putative CRCSC: CD133, CD29, CD44, CD166 (ALCAM), EpCAM, ALDH1A1 and ALDH1B1 (**Table [1](#T1){ref-type="table"}**). These markers represent all reported CRCSC. Despite the potential of CRCSC\'s to be utilized as clinically relevant biomarkers, little is known about the prognostic value of non-CD133 CRCSC markers[@B23]. Notwithstanding, the CSC hypothesis may herald a paradigm shift in screening and early detection in CRC once the precise role of CRCSC markers is further established. Therefore, we hypothesized that CRCSC markers can be used as biomarkers to predict disease progression, and identify patients at risk for recurrence.

Until more effective therapies can be developed, one strategy for improving outcomes while reducing the socio-economic burden of CRC is to develop novel strategies for CRC screening that will result in higher rates of early CRC detection. Another strategy to improve outcomes in this era of patient-centered, quality-driven, value-based purchasing in oncology is to identify those patients who would most benefit from adjuvant treatments and intensive post-treatment surveillance protocols. There is an acute need for highly sensitive and specific biomarkers capable of identifying patients with early CRC that are highly likely to recur and/ or metastasize, and patients who are likely to progress despite adjuvant therapy. Such risk stratification would: \[1\] spare low risk patients likely cured by surgery alone the toxicity of systemic therapy; \[2\] identify and treat with chemotherapy at-risk patients with early stage CRC; and, \[3\] limit treatments to patients with clinically latent (stable) residual disease and reserve additional therapy for treatment-responsive disease progression [@B24]. The aim of this pilot study was to analyze the expression profile of non-CD133 putative CRCSC markers and determine a possible role for CRCSC as risk-stratifying, prognostic biomarkers.

Methods
=======

Patients
--------

We used a colorectal Tissue Micro Array (TMA) with corresponding survival and clinicopathological data (catalog number C0951, US Biomax, Rockville, MD, USA). The TMA included 30 patients with double core tissue sites of primary colorectal cancers with matched normal colorectal tissue in eight patients and matched metastatic tissue in ten other patients. Patient characteristics are depicted in table [2](#T2){ref-type="table"}.

Immunohistochemistry
--------------------

Immunohistochemistry (IHC) was performed using previously described techniques[@B25]. We performed immunohistochemistry for CD29, CD44, CD166, EpCam, ALDH1A1 and ALDH1B1 (Table [1](#T1){ref-type="table"}). Staining was performed on Leica Biosystems (IL, USA) Bond Autostainer. The primary antibodies used in this study included anti-CD29 (1:200, Abcam, Cambridge, MA, USA), anti-CD44 (1:400, Abcam, Cambridge, MA, USA), anti-CD166 (1:40, Abcam, Cambridge, MA, USA), anti-EpCam (1:100, Cell Signaling, Danvers, MA, USA), anti-ALDH1A1 (1:250, Epitomics, Burlingame, CA, USA), anti-ALDH1B1 (1:400, Sigma, St. Louis, MO, USA). TMAs were single stained for each biomarker with matched positive and negative controls[@B25]. A pathologist who was blinded to the clinical outcomes evaluated individual samples within the TMAs. Each individual sample was scored quantitatively evaluating the proportion of positive cells, and the intensity of positively stained cells. The percent of positive cells was graded using the following rubric: 0 = \<10%, 1 = 10 - 24%, 2 = 25 - 49%, 3 = 50 - 74%, 4 = 75 - 100%. The intensity of positive stained cells was graded using the following rubric: 0 = no staining, 1 = diminutive intensity, 2 = low intensity, 3 = intermediate intensity, 4 = high intensity. The pathologic score for each sample is represented by the sum of these two values: this sum is referred to as the combined IHC staining score (CSS).

Statistical Analyses
--------------------

CSS was computed for each sample and each marker. In cases in which there were two samples obtained for a given patient/site, the average of the sum of the two scores was used. The association between the pathologic score and overall survival (OS) of patients was determined based on data from the 30 primary sites. The probability of survival as a function of time was determined by the Kaplan-Meier method, and the statistical significance was determined by the log-rank method. In cases for which the initial grouping of patients\' scores or clinical data was reduced to two groups in order to identify a better grouping of subjects based on prognostic ability, the p-values for the revised analysis of dichotomized groups were adjusted for multiple testing, which would be performed to arrive at the identified final grouping. A Cox proportional hazards model analysis was performed to determine the joint association of CSSs found to be significantly associated with OS in the initial univariate analyses after adjusting for important clinical factors.

Within the 30 primary specimens, the association between the CSS and tumor grade was determined with an exact Kruskal-Wallis test. The association between the CSS and stage was determined by a Jonckheere-Terpstra test for trend. The association between the CSS and sex was determined by an exact Wilcoxon rank sum test, while Spearman rank correlation was used to determine the correlation between the CSS and age. Analyses to compare the CSS between the matched primary sites and the metastatic sites, or the primary sites and the normal sites, were performed on paired samples using a Wilcoxon signed rank test. Comparisons of CSS between metastatic and normal samples were made with a Wilcoxon rank sum test, since these data are only from different patients. All p-values are two-tailed and presented without adjustment for multiple comparisons.

Results
=======

All six CRCSC markers were assessed for association with overall survival. Out of the six, only loss of CD29 expression was potentially associated with a significant difference in OS (CSS 3-7 vs. CSS \> 7.5, median 32 months vs. not reached, respectively; p = 0.052 after adjustment for the grouping identified, **Figure [1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}**). Increased ALDH1A1showed a trend towards decreased OS (p=0.16, **Table [3](#T3){ref-type="table"}**). Age, sex, and pathologic grade (poorly, moderately, well differentiated) were not significantly associated with OS. Stage of disease was associated with OS; patients with AJCC Stage 2 or 3 disease had a significantly better prognosis than those with Stage 4 disease (Median OS: not reached vs. 11 months; p = 0.0009, adjusted for the grouping of stages). The joint association between CD29 and Stage (2-3 vs. 4) was evaluated in a Cox proportional hazards model. After adjusting for stage (p=0.0076, Hazard ratio 5.06; 95% CI for HR: 1.54 to 16.65), loss of CD29 expression was marginally associated with poor OS (p = 0.098; Hazard ratio=0.28; 95% CI for HR: 0.06 to 1.27; **Figure [2](#F2){ref-type="fig"}**).

Univariate analyses of the CSS were performed for the 30 primary tissue specimens in order to assess the interaction between the CRCSC biomarkers and the level of pathologic differentiation (poorly, moderately, well differentiated). Out of the six CRCSC, only ALDH1B1 showed a statistically significant association with tumor differentiation. ALDH1B1 expression was significantly increased in poorly and/or moderately differentiated tumors as compared to well-differentiated or mucinous tumors (p = 0.011). Analysis of the association between CSS and stage was performed. Only increased ALDH1A1 showed an association between increasing expression level and increasing stage (p = 0.04). The combination of CD29 and ALDH1B1 was not associated with a difference in OS.

When comparing normal colon tissue to metastatic tissue sites from different patients, CD29 expression was higher in normal tissue (p = 0.014), whereas ALDH1B1 expression was significantly higher in metastatic tissue (p = 0.001). In comparing primary tumors to their matched patient metastatic sites, none of the CSS differed significantly between two samples from the same patient. However, comparison of normal colon tissue to primary tumor showed that increased ALDH1B1 expression was associated with the primary tumors (p = 0.008).

Assessment of the six CRCSC markers and their relation to lymph node status was performed. Advanced AJCC lymph node stage (N0 vs. N1-2) was associated with decreased CD29 (p = 0.08) expression, while EpCAM tended to decrease with increased nodal stage, from N0 to N1 to N2; p=0.06.

Localization of expression was different between the various CRCSC markers, and consistent with previous reports and their associated functions. ALDH1A1 and ALDH1B1 expression was intracellular, while EpCAM expression was at the cell surface. CD29, CD44 and CD166 had a combination of intracellular and cell surface expression.

Discussion
==========

Two fundamental issues regarding colorectal carcinogenesis remain unanswered. First, the level of differentiation in the initiating neoplastic cell has not been well described i.e. colonic stem cell vs. differentiated mature colonic mucosal epithelial cell. Second, since tumors are well known to be composed of a heterogeneous group of cells, the specific identity of tumor cells that lead to lymph-node involvement, and metastatic disease is not well characterized.[@B20] Recently, attempts to address both of these issues pragmatically, which are critical to our understanding of tumor biology, have resulted in the description of cancer stem cells. While the stochastic model of tumorigenesis holds that every cell within the tumor population is capable of tumor initiation and propagation, the cancer stem cell model proposes that only a small fraction of cells possesses the ability to initiate cancer growth and promote metastatic dissemination[@B20].

There are various methods of CSC identification *in vitro*; however, there is currently no consensus on a universally acceptable method[@B15]-[@B18],[@B20],[@B23]. For technical reasons, the most commonly utilized method of identification involves separating cells based on proteins thought to be associated with the cancer stem cell phenotype[@B26]. Detection of sub-populations of cells such as CRCSC in regional nodes negative for tumor cells by conventional histopathology, or as circulating cells in the blood or bone marrow, is likely to increase accuracy of both cancer staging and prognosis. While some studies have linked CSC markers to prognosis, there remains no definitive association between putative CSC markers and disease behavior, disease progression, or survival. An association between putative CRCSC markers and survival could not only improve cancer screening and early detection, but also help define optimal post-treatment follow up. Equally as important, CRCSC markers could potentially tailor more efficacious treatment modalities to those patients who stand to benefit most, such as at-risk node-negative (early stage) CRC patients who are prone to recur.

Molecular biomarkers provide potential benefits because they enable identification of specific cell types and cell populations that are associated with disease behavior and clinical outcomes [@B26]. Methods of cancer stem cell identification are based on markers specific for normal progenitor or stem cells in the same organ[@B27]. The adult stem cells of the colon are of particular interest because they sustain the perpetual self-renewal of healthy colonic epithelium and are therefore able to acquire the number of mutations required for carcinogenesis[@B26]. Although initial reports identified CD133 as a reliable CSC marker in colorectal cancer, subsequent studies have shown that CD133 expression is not restricted to rare cell subsets and it is detectable in a large majority of tumor cells, irrespective of their tumorigenicity[@B23]. Lugli et al also stated that neither over-expression nor loss of CD133 was significantly associated with tumor progression or survival[@B23]. Alternatively, CD29, C44, EpCAM, CD166, ALDH1A1 and ALDH1B1 were reported to identify another CSC pool[@B23],[@B28]. Presence of these proteins has been associated with characteristics of stemness both *in vitro* and *in vivo* [@B20]. Cells positive for these markers have been shown to generate tumors recapitulating the primary tumor with increased clonogenic ability and multi-lineage potential [@B20]. This subset of cells has also been associated with tumor stage, differentiation, invasiveness, metastasis formation, and prognosis[@B20]. However, there is a paucity of longitudinal data in order to more fully understand the related disease biology, as is presented in our study.

Uncertainty remains as to whether CSC markers exclusively delineate the stem cell population and whether they can predict disease behavior [@B26], [@B4]. In normal colon, CD29 has been observed in the lower parts of the crypts and therefore has been hypothesized to be a mucosal progenitor cell marker[@B29]. The combination of CD24 and CD29 has been suggested to identify the tumor initiating fraction in mouse colon carcinomas[@B29] and it is proposed that CD29 may promote cancer progression by inducing invasion, migration and metastasis through regulation of the tumor microenvironment [@B29],[@B30]. Zou et al also stated that the CD133+CD29+ cellular fraction up-regulated self-renewal, proliferation and differentiation, and therefore reported CD29 to be a new stem cell marker for colon cancer,[@B30] although its full biological function has yet to be elucidated. Here we present the first report of the possible association between CD29 expression and overall survival in CRC, which remains to some degree even after adjustment for stage in this limited size study.

CD44, the first stem cell marker to be identified in breast cancer, has long been thought to be a marker of tumor invasiveness and metastasis, and more recently has been described as a potential CRCSC marker[@B21],[@B23]. CD44 is a transmembrane glycoprotein that can act as a receptor for extracellular matrices such as hyaluronic acid; it is a downstream target of the Wnt/B-catenin pathway[@B21]. High expression of CD44 in malignant colonic epithelial cells has been associated with tumor virulence; knockdown of CD44 in primary colon cancer cell lines reduced clonogenicity *in vitro* and tumorigenicity *in vivo*[@B29]. Currently, it is not known whether CD44 is a specific marker for stem cells, as a large population of CD44-exressing cells within a tumor has many splice variants[@B21]. Early reports of the CD44 gene and its splice variants describe decreased overall survival in patients with increased expression levels of the gene or its related protein. More recent results, however, are inconsistent; some suggest either no role for CD44, others demonstrate a worse clinical outcome with loss of protein expression [@B31],[@B32],[@B33],[@B23]. Further, some have identified increased expression of CD44 in colon along the progression from normal colonic epithelium to adenoma to carcinoma[@B33],[@B23]. We did not find CD44 to be prognostic.

Epithelial cell adhesion molecule (EpCAM) is a transmembrane glycoprotein mediating epithelium-specific intercellular adhesion. It is also a molecule involved in cell signaling, migration, proliferation and differentiation[@B34]. As EpCAM is expressed wholly in epithelium-derived cancers, it has been reported as a diagnostic marker[@B34]. Enhanced EpCAM expression has been linked to advanced cancer stage and worse overall survival[@B34], specifically for breast cancer and gallbladder cancer[@B35],[@B36]. EpCAM expression has also been linked to higher primary tumor grade and inferior local and distant recurrence free survival in rectal cancer[@B37]. Lugli et al. also noted EpCAM to be a prognostic marker; however, they found a decreased expression of EpCAM to be prognostic. In addition, decreased EpCAM expression was found to be significantly associated with infiltrating tumor margin, tumor invasion, and presence of lymph node metastasis[@B23]. Similarly, we found that decreased EpCAM expression is associated with increasing lymph node stage (N0 vs. N1 vs. N2).

CD166 expression can be used to further select CSC\'s within the EpCAM(+)CD44(+) population [@B21]. There appears to be heterogeneous expression of CD166 in CRC and the expression level is associated with poor clinical outcomes. It has been hypothesized that this effect is possibly mediated by CD166 regulation of cell-to-cell interactions[@B29]. In immunodeficient mice, CD44+CD166+ colon cancer cells display high tumor initiating potential[@B29]. Patel et al. found a significant increase in CD166 expression in adenomatous glands and an age-dependent increase in CD44 and CD166 expression. This was also associated with the number of colon polyps[@B23],[@B38]. Weichert et al. described increased expression of CD166 in tumor tissue, and, in a group of 111 colorectal cancer cases, observed a between CD166 expression and shortened overall survival[@B23],[@B39]. These findings suggest a role for both CD44 and CD166 in the colon adenoma to carcinoma sequence. It is possible that because of the small number of patients analyzed in this study an association between CD44, CD166 and outcomes could not be elucidated.

CD24 has also been implicated in CRCSC\'s. Choi et al examined 523 colorectal adenocarcinomas of various stages and found significant correlation between CD24 expression and degree of differentiation[@B19],[@B40]. Other studies have shown that the degree of colorectal tumor CD24 expression is associated with lymph node metastasis and shortened patient survival [@B19],[@B41],[@B42]. We chose not to use CD24 in this study. Although there may be a relationship between CD24 and oncologic outcome, the evidence for CD24 as CRCSC marker is less convincing.

ALDH1 has been reported as a cancer stem cell marker in pancreatic, breast, prostate, and lung cancer, multiple myeloma and leukemia. More recently ALDH1 was identified as a CRCSC marker[@B21]. ALDH1 functions by catalyzing the irreversible oxidation of a range of aliphatic and aromatic aldehydes to their corresponding carboxylic acids[@B27]. High ALDH1 activity is detected in stem and progenitor cells of various lineages. Enhanced ALDH1 expression was found in areas where epithelial progenitor cells localize within normal breast, colon and stomach[@B27]. Various groups have reported that high ALDH1 expression is associated with reduced survival times in breast, lung, pancreas, bladder and prostate cancer patients[@B27]. Deng et al. found that ovarian cancer patients with high ALDH1 had shorter disease free and overall survival compared to those with low ALDH1 (p = 0.0036 and p = 0.0023, respectively)[@B27]. Lugli et al. also noted that increased ALDH1 expression is associated with higher tumor grade[@B23]. We similarly found an association between ALDH expression and disease behavior.

Although this study is the first to analyze the association between specific biomarkers within a panel of six CRCSC markers and overall survival, the study has its limitations, particularly a small overall sample size. This specifically reduced our ability to describe tumor characteristics and behaviors according to multi-marker phenotype of the investigated molecules, and required us to conduct the analysis according to each marker individually. This parsimonious analytical approach was done of necessity, as multi-marker phenotypes in tumor tissues are notably heterogeneous. The small number of matched normal controls and matched metastatic tissue cores is another limitation of this study. Finally, we were constrained by needing to use a retrospective study design. For this reason, we regard this study as hypothesis generating in nature, and report our findings in the context of a pilot study. Therefore, the data should be interpreted with caution. Further prospective investigation is needed to validate CRCSC as biomarkers.

The CSC hypothesis appears to have a promising role in CRC tumor biology, despite the remaining unanswered questions related to this novel premise. By focusing on the identification and treatment of tumor progenitor cells, we may ultimately be able to improve screening, early detection, treatment, and prognostication[@B19]. Further identification of novel cell surface or cytoplasmic markers associated with CRCSC, and validation of known CRCSC could be useful in identifying tumors with poor prognosis. This approach could further enhance our ability to assess response to therapy and optimize treatment selection and intensity of post-treatment surveillance and follow-up. In order to translate these findings into clinical practice, prospective comprehensive analysis of a panel of CRCSC expression in large groups of patients is imperative[@B23]. Moreover, there remains a paucity of data evaluating the prognostic significance of the co-expression of multiple CRCSC within the same tumor, nodal and distant metastases within the same patients [@B14],[@B23].

Conclusion
==========

In this study, we have evaluated the relationship between the expression of six CRCSC markers, clinically relevant features and outcomes. Our findings suggest that decreased CD29 expression, decreased EpCAM expression and increased ALDH1A1 and ALDH1B1 expression may represent suitable risk-stratifying worth exploring as prognostic biomarkers in CRC. These findings may lend themselves to a new strategy of individualized adjuvant therapy selection and post-treatment surveillance aimed at identifying patients with the highest likelihood of disease recurrence or progression based on CRCSC marker expression within the primary tumor.

The CSC hypothesis may herald a paradigm shift in oncologic diagnosis and treatment. This pilot study shows that putative CRC stem cell markers may have a role in predicting the behavior of CRC and estimating clinical outcomes. Prospective studies properly powered based on this study should be undertaken to determine the significance of these early findings.
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![A. Immunohistochemistry anti-CD29 staining, CSS 5 at 8x and 20x ocular. B. Immunohistochemistry anti-29 staining, CSS 8 at 8x and 20x ocular. (CSS: combined staining score).](jcav03p0231g01){#F1}

![Association of overall survival and CD29 expression of the primary colorectal cancer tumor. Combined staining score was calculated as the sum of antibody intensity (0 - 4) and percent cells positive (0 - 4).](jcav03p0231g02){#F2}

###### 

Summary of putative CRC Stem Cell Markers.

  ----------------------------------------------------------------------------------------------------------------------------------
  Marker    Gene        Function
  --------- ----------- ------------------------------------------------------------------------------------------------------------
  CD29      *ITGB1*     \- Integrin that mediates cell-ECM adhesion and is involved in homing to sites of inflammation\
                        -Involved in cell growth, differentiation, migration and death

  CD44      *CD44*      -Cell surface glycoprotein involved in cell adhesion and migration\
                        -Associated with malignant progression (adenoma to carcinoma): involved in cell migration through the ECM\
                        -Enhanced expression in breast cancer epithelial cells facilitated tumor cell migration

  CD166     *ALCAM*     -Involved in neuronal extension, embryonic hemopoiesis, embryonic angiogenesis\
                        -Cell adhesion molecule\
                        -Associated with adenoma to carcinoma development

  EpCAM     *EPCAM*     -Cell adhesion molecule\
                        -Linked to Cadherin-Cathenin pathway and Wnt pathway\
                        -Expression data linked to poorer survival times in several tumor types including breast cancer\
                        -Loss of expression associated with aggressive rectal cancer

  ALDH1A1   *ALDH1A1*   -Detoxifying enzyme responsible for the oxidation of intracellular aldehydes\
                        -Early differentiation of stem cells\
                        -Involved in resistance to chemotherapy (alkylating agents)\
                        -Malignant prostate stem cells and predictor of prostate cancer patient outcome

  ALDH1B1   *ALDH1B1*   -Detoxifying enzyme responsible for the oxidation of intracellular aldehydes\
                        -Early differentiation of stem cells\
                        -Higher expression in CRC
  ----------------------------------------------------------------------------------------------------------------------------------

Abbreviations: CD, cluster of differentiation; ALDH, aldehyde dehydrogenase-1; ECM, extra cellular matrix; CRC, colorectal cancer.

###### 

Summary of patient characteristics (n = 30).

  -----------------------------------------------------------------------
  Clinicopathological Feature   Outcome                 Frequency N (%)
  ----------------------------- ----------------------- -----------------
  Age (years; n = 29)           Mean (range)            56 (35 - 76)

  Gender (n = 30)               Male                    17 (57)

  Female                        13 (43)                 

  Location (n = 30)             Sigmoid colon           11 (36.6)

  Ascending colon               8 (26.6)                

  Transverse colon              3 (10)                  

  Descending colon              2 (6.6)                 

  Cecum                         2 (6.6)                 

  Rectum                        4 (13.3)                

  Pathological Grade (n = 30)   Poorly differentiated   1 (3.3)

  Moderately differentiated     18 (60)                 

  Well differentiated           8 (26.6)                

  Mucinous Adenocarcinoma       3 (10)                  

  Stage (n = 30)                IIA                     7 (23.3)

  IIIB                          10 (33.3)               

  IIIC                          7 (23.3)                

  IV                            6 (20)                  

  T Classification (n = 30)     pT3                     25 (83.3)

  pT4                           5 (16.6)                

  N Classification (n = 30)     N0                      7 (23.3)

  N1                            13 (43.3)               

  N2                            10 (33.3)               

  Sites of Metastatic Tissue\   Lung                    2
  (n = 8)                                               

  Lymph node                    5                       

  Ovary                         3                       

  Follow Up (months)            Median (Range)          113 (0 - 130)
  -----------------------------------------------------------------------

###### 

Association of CRCSC with survival and clinical characteristics. (Overall Survival Statistics)

  Marker                                                                                                   Expression   p-value                                      
  -------------------------------------------------------------------------------------------------------- ------------ -------------------------------------------- --
  **Overall Survival Statistics**                                                                                                                                    
  CD29                                                                                                     Decreased    0.052 (adjusted for grouping)                
  CD44                                                                                                     \-           0.69                                         
  CD166                                                                                                    \-           0.33                                         
  EpCAM                                                                                                    \-           0.77                                         
  ALDH1A1                                                                                                  \-           0.16                                         
  ALDH1B1                                                                                                  \-           0.27                                         
  **Pathologic Differentiation (poorly/moderately differentiated vs. well differentiated vs. mucinous)**                                                             
  CD29                                                                                                     \-           0.55                                         
  CD44                                                                                                     \-           0.94                                         
  CD166                                                                                                    \-           0.75                                         
  EpCAM                                                                                                    \-           0.09                                         
  ALDH1A1                                                                                                  \-           0.30                                         
  ALDH1B1                                                                                                  Increased    0.011                                        
  **Increasing Stage of Disease**                                                                                                                                    
  CD29                                                                                                     \-           0.19                                         
  CD44                                                                                                     \-           0.38                                         
  CD166                                                                                                    \-           0.77                                         
  EpCAM                                                                                                    \-           0.34                                         
  ALDH1A1                                                                                                  Increased    0.04                                         
  ALDH1B1                                                                                                  \-           0.97                                         
  **Normal vs. Metastatic Tissue**                                                                                                                                   
  CD29                                                                                                     Decreased    0.014                                        
  CD44                                                                                                     \-           0.26                                         
  CD166                                                                                                    \-           0.23                                         
  EpCAM                                                                                                    \-           0.10                                         
  ALDH1A1                                                                                                  \-           0.24                                         
  ALDH1B1                                                                                                  Increased    0.001                                        
  **Normal vs. Primary Tumor Tissue**                                                                                                                                
  CD29                                                                                                     \-           0.44                                         
  CD44                                                                                                     \-           0.84                                         
  CD166                                                                                                    \-           0.13                                         
  EpCAM                                                                                                    \-           0.50                                         
  ALDH1A1                                                                                                  Increased    0.06                                         
  ALDH1B1                                                                                                  Increased    0.008                                        
  **Lymph Node Stage**                                                                                                                                               
  CD29                                                                                                     Decreased    0.08 (0 vs. 1+2; p=0.11 for 0 vs. 1 vs. 2)   
  CD44                                                                                                     \-           0.57                                         
  CD166                                                                                                    \-           0.52                                         
  EpCAM                                                                                                    Decreased    0.06                                         
  ALDH1A1                                                                                                  \-           0.47                                         
  ALDH1B1                                                                                                  \-           0.65                                         
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